凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
华兰生物(002007)公告正文

华兰生物2007年第三季度季度报告

公告日期 2007-10-25
股票简称:华兰生物 股票代码:002007
    
                                华兰生物工程股份有限公司2007年第三季度季度报告全文

    1重要提示
    1.1本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性负个别及连带责任。
    1.2没有董事、监事、高级管理人员对本报告内容的真实性、准确性、完整性无法保证或存在异议。
    1.3公司全体董事亲自出席了本次审议季度报告的董事会。
    1.4公司第三季度财务报告未经会计师事务所审计。
    1.5公司负责人安康先生、主管会计工作负责人王启平先生及会计机构负责人桑莉女士声明:保证季度报告中财务报告的真实、完整。
    2公司基本情况
    2.1主要会计数据及财务指标

                                                                                                     单位:(人民币)元
                                              2007.9.30                   2006.12.31                增减幅度(%)
              总资产                              957,501,788.89                816,570,601.51                      17.26%
             股东权益                             643,364,944.22                555,725,915.60                      15.77%
               股本                               180,900,000.00                150,750,000.00                      20.00%
            每股净资产                                     3.556                         3.686                      -3.53%
                                        2007年7-9月       比上年同期增减(%)      2007年1-9月       比上年同期增减(%)
            营业总收入                     102,201,543.86               15.83%         273,533,404.27                3.13%
              净利润                        36,058,046.54               52.50%          87,639,028.62               36.57%
   经营活动产生的现金流量净额                 -                     -                   77,926,181.65              218.45%
 每股经营活动产生的现金流量净额               -                     -                           0.431               77.37%
           基本每股收益                             0.199              -15.32%                  0.484              -24.26%
 扣除非经常性损益后的基本每股收
                                              -                     -                           0.489              -25.53%
                 益
           稀释每股收益                             0.199              -15.32%                  0.484              -24.26%
           净资产收益率                             5.60%                1.23%                 13.62%                1.75%
 扣除非经常性损益后的净资产收益
                                                   5.70%                 1.10%                 13.74%                1.55%
                 率
非经常性损益项目
                                                                                                     单位:(人民币)元
                       非经常性损益项目                                              2007年1-9月金额
营业外收支净额                                                                                                 -743,670.19
                              合计                                                                             -743,670.19

    2.2报告期末股东总人数及前十名无限售条件股东持股情况表

                                                                                                               单位:股
                  股东总数                                                                                           3,348
           前10名无限售条件股东持股情况
                  股东名称                          持有无限售条件股份数量                         股份种类
新乡市华兰生物技术有限公司                                                 9,045,000           人民币普通股
新乡市金康生物科技开发有限公司                                             9,045,000           人民币普通股
香港科康有限公司                                                           9,045,000           人民币普通股
交通银行-汉兴证券投资基金                                                 8,315,503           人民币普通股
北京东方世辰生物技术有限公司                                               8,009,280           人民币普通股
中国工商银行-汇添富成长焦点股票型证券                                                         
                                                                           5,084,506           人民币普通股
投资基金                                                                                       
汉盛证券投资基金                                                           4,383,032           人民币普通股
中国人寿保险股份有限公司-分红-个人分                                                         
                                                                           4,332,235           人民币普通股
红-005L-FH002深                                                                                
中国工商银行-汇添富均衡增长股票型证券                                                         
                                                                           4,276,454           人民币普通股
投资基金                                                                                       
中国工商银行-安信证券投资基金                                             3,600,000           人民币普通股

    3重要事项
    3.1公司主要会计报表项目、财务指标大幅度变动的情况及原因
    √适用□不适用
    1、管理费用较上年同期增长1238.95万元,增幅88.44%,主要系本期合并报表新增九家单采血浆有限公司。
    2、财务费用较上年同期增长113.71万元,增幅450.55%,主要系上期取得财政贴息收入冲减了财务费用而本期无此类收入发生所致。
    3、资产减值损失较上年同期增长126.79万元,增幅45643%,主要原因系子公司往来应收款项增加所致。
    4、营业外收入较上年同期减少81.67万元,降幅99.61%,主要原因系上期取得补贴收入而本期无此收入所致。
    5、营业外支出较上年同期减少379.02万元,降幅82.94%,主要原因系上期固定资产报废支出所致。
    6、利润总额较上年同期增加2237.32万元,增幅34.85%,主要原因一是血浆综合利用率提高;二是部分产品平均售价较上年同期有所增长所致。
    3.2重大事项进展情况及其影响和解决方案的分析说明
    √适用□不适用
    根据中国证监会证监公司字(2007)28号文《开展加强上市公司治理专项活动有关事项的通知》、深圳证券交易所《关于做好加强上市公司治理专项活动有关工作的通知》的要求,公司于2007年6月至7月开展了公司治理情况自查活动,并严格对照《公司法》、《证券法》等有关法律法规,以及公司章程等内部规章制度,对公司治理情况进行了认真的自查,公司治理自查报告和整改计划》已刊登在《证券时报》和巨潮资讯网(www.cninfo.com.cn)。
    3.3公司、股东及实际控制人承诺事项履行情况
    √适用□不适用
    1、公司或持有公司股份5%以上的股东在报告期内没有发生或以前期间发生但延续报告期的对公司经营成果、财务状况可能发生重要影响的承诺事项。
    2、公司原非流通股东在股权分置改革过程中做出的特殊承诺及其履行情况:

      股东名称                                  特殊承诺                                  履约情况        承诺履行情况
                     1、若华兰生物2005年度经审计后的净利润较2004年增长低于20%
                     时或者华兰生物2005年度财务报告被出具非标准无保留意见审
                     计报告时,触发追送股份承诺条款:由原非流通股股东将其执行
全体原非流通股东                                                                    未达到履约条件               -
                     对价安排后的存量股份中的165万股(相当于按照股权分置改革
                     前流通股3300万股每10股追送0.5股)向无限受条件的流通股股
                     东追送股份。
                     2、在实施股权分置改革方案之后,将向2005年度股东大会提出如
                     下分红议案,并保证在股东大会表决时对该议案投赞成票:华兰
全体原非流通股东                                                                           已履约         严格履行承诺
                     生物2005年度的利润分配比例将不低于2005年度实现的可分配
                     利润(非累计可分配利润)的70%。
                     自改革方案实施之日起,至少在十二个月内不上市交易或者转
                     让,并在该期限届满后12个月内,若通过深圳证券交易所交易系
                     统出售华兰生物股票,出售价格不低于12.25元。同时,当华兰
新乡市华兰生物技术
                     生物派发红股、转增股本、增资扩股(包括可转换债券转换的股              履约中         严格履行承诺
有限公司
                     本)、配股、派息等情况使股份数量或股东权益发生变化时,相
                     应调整最低出售价格。(公司2006年中期及2006年度转增股本后,
                     价格调整为6.53元)。
                     自改革方案实施之日起,至少在十二个月内不上市交易或者转
北京东方世辰生物技让,并在该期限届满后24个月内,通过证券交易所挂牌交易出售
                                                                                           履约中         严格履行承诺
术有限公司           股份,出售数量占其所持有本公司股份总数的比例,在每季度不
                     超过百分之二十。
                     自改革方案实施之日起,至少在十二个月内不上市交易或者转
成都夸常科技有限公让,并在该期限届满后24个月内,通过证券交易所挂牌交易出售
                                                                                           履约中         严格履行承诺
司                   股份,出售数量占其所持有本公司股份总数的比例,在每季度不
                     超过百分之二十。
                     自改革方案实施之日起,至少在十二个月内不上市交易或者转
新乡市纪龙广告有限让,并在该期限届满后24个月内,通过证券交易所挂牌交易出售
                                                                                           履约中         严格履行承诺
公司                 股份,出售数量占其所持有本公司股份总数的比例,在每季度不
                     超过百分之二十。
3.4对2007年度经营业绩的预计
                                                                                                     单位:(人民币)元
                             净利润比上年增长幅度小于30%
对2007年度经营业绩的预计
                             净利润比上年同期增长幅度小于30%。
2006年度经营业绩             净利润(未按新会计准则调整)                                                    79,001,163.92
业绩变动的原因说明           公司产品价格及血浆综合利用率上升所致。

    3.5证券投资情况
    □适用√不适用
    4附录
    4.1资产负债表
    编制单位:华兰生物工程股份有限公司                          2007年09月30日                           单位:(人民币)元

                                                   期末数                                        期初数
             项目
                                         合并                 母公司                  合并                  母公司
流动资产:
  货币资金                              189,192,754.22          87,182,753.89         201,587,646.13        154,961,131.08
  结算备付金
  拆出资金
  交易性金融资产
  应收票据                                6,480,814.71           5,039,781.52          13,536,268.78         13,086,268.78
  应收账款                               52,171,053.19          46,433,002.29          38,000,993.44         36,284,704.44
  预付款项                              164,494,047.87         174,710,642.32         145,447,985.95        164,054,907.82
  应收保费
  应收分保账款
  应收分保合同准备金
  应收利息
  其他应收款                             25,027,360.11         101,311,327.54           4,076,529.14         18,881,600.99
  买入返售金融资产
  存货                                   96,720,223.12          76,213,055.29          81,081,622.68         73,165,475.45
  一年内到期的非流动资产
  其他流动资产                                                                             55,312.45             55,312.45
流动资产合计                            534,086,253.22         490,890,562.85         483,786,358.57        460,489,401.01
非流动资产:
  发放贷款及垫款
  可供出售金融资产
  持有至到期投资
  长期应收款
  长期股权投资                                                 170,198,885.39                               105,572,385.39
  投资性房地产
  固定资产                              241,924,064.50         128,686,908.40         218,094,238.40        120,400,018.30
  在建工程                              117,252,487.15          30,200,888.72          84,159,723.15         19,483,641.01
  工程物资                                  888,421.64                                    370,410.40
  固定资产清理
  生产性生物资产
  油气资产
  无形资产                               62,489,392.06          23,435,331.50          29,273,632.82          9,991,933.85
  开发支出
  商誉
  长期待摊费用                                                                            284,341.42
  递延所得税资产                            861,170.32             522,436.89             601,896.75            581,584.29
  其他非流动资产
非流动资产合计                          423,415,535.67         353,044,450.90         332,784,242.94        256,029,562.84
资产总计                                957,501,788.89         843,935,013.75         816,570,601.51        716,518,963.85
流动负债:
  短期借款                              160,000,000.00         110,000,000.00         140,000,000.00         80,000,000.00
  向中央银行借款
  吸收存款及同业存放
  拆入资金
  交易性金融负债
  应付票据                                                                              4,866,301.68          4,866,301.68
  应付账款                               32,753,065.11          28,617,617.00          41,205,282.12         34,669,518.53
  预收款项                                4,416,568.67           3,099,351.01           1,359,803.84          1,278,503.84
  卖出回购金融资产款
  应付手续费及佣金
  应付职工薪酬                           11,098,967.01          10,660,969.40          13,383,390.18         13,382,390.18
  应交税费                               15,814,405.53          14,879,344.82           5,166,505.66          5,009,656.97
  应付利息
  其他应付款                              4,218,112.96          22,459,513.35          17,546,032.75         17,446,677.05
  应付分保账款
  保险合同准备金
  代理买卖证券款
  代理承销证券款
  一年内到期的非流动负债
  其他流动负债
流动负债合计                            228,301,119.28         189,716,795.58         223,527,316.23        156,653,048.25
非流动负债:
  长期借款                               50,000,000.00
  应付债券
  长期应付款
  专项应付款                              4,140,000.00           4,140,000.00           4,140,000.00          4,140,000.00
  预计负债
  递延所得税负债
  其他非流动负债
非流动负债合计                           54,140,000.00           4,140,000.00           4,140,000.00          4,140,000.00
负债合计                                282,441,119.28         193,856,795.58         227,667,316.23        160,793,048.25
所有者权益(或股东权益):
  实收资本(或股本)                    180,900,000.00         180,900,000.00         150,750,000.00        150,750,000.00
  资本公积                              196,371,732.03         196,371,732.03         226,521,732.03        226,521,732.03
  减:库存股
  盈余公积                               34,458,182.22          34,458,182.22          34,458,182.22         34,458,182.22
  一般风险准备
  未分配利润                            231,635,029.97         238,348,303.92         143,996,001.35        143,996,001.35
  外币报表折算差额
归属于母公司所有者权益合计              643,364,944.22         650,078,218.17         555,725,915.60        555,725,915.60
少数股东权益                             31,695,725.39                                 33,177,369.68
所有者权益合计                          675,060,669.61         650,078,218.17         588,903,285.28        555,725,915.60
负债和所有者权益总计                    957,501,788.89         843,935,013.75         816,570,601.51        716,518,963.85
4.2本报告期利润表
编制单位:华兰生物工程股份有限公司                            2007年7-9月                          单位:(人民币)元
                                                    本期                                       上年同期
             项目
                                         合并                 母公司                  合并                  母公司
一、营业总收入                          102,201,543.86         102,141,224.61          88,233,322.98          83,754,502.55
其中:营业收入                          102,102,220.20         102,041,900.95          87,955,348.62          83,476,528.19
       利息收入
       已赚保费
       手续费及佣金收入
二、营业总成本                           58,808,646.08          58,239,901.41          60,736,574.53          55,225,777.44
其中:营业成本                           40,477,244.53          44,304,428.48          49,267,213.55          44,604,784.08
       利息支出
       手续费及佣金支出
       退保金
       赔付支出净额
       提取保险合同准备金净

       保单红利支出
       分保费用
       营业税金及附加                       214,719.62                                     12,205.47
       销售费用                           7,328,935.21           7,283,465.40           6,261,754.42           6,260,843.42
       管理费用                           9,936,756.29           5,980,099.21           3,973,728.32           3,478,861.93
       财务费用                             753,928.44             574,846.33           1,030,354.44            723,381.24
       资产减值损失                                                                        33,411.56
  加:公允价值变动收益(损失
以"-"号填列)
       投资收益(损失以"-"号
                                                                                                               -777,359.52
填列)
         其中:对联营企业和合
营企业的投资收益
     汇兑收益(损失以"-"号填
列)
三、营业利润(亏损以"-"号填
                                         43,392,897.78          43,901,323.20          27,496,748.45          27,751,365.59
列)
  加:营业外收入                              1,000.00               1,000.00             677,690.79             677,690.79
  减:营业外支出                            563,646.25             530,707.18           2,185,686.56           2,185,686.56
     其中:非流动资产处置损失                                                           2,113,096.82           2,113,096.82
四、利润总额(亏损总额以"-"
                                         42,830,251.53          43,371,616.02          25,988,752.68          26,243,369.82
号填列)
  减:所得税费用                          6,901,435.84           6,700,958.48           2,610,110.53           2,599,005.75
五、净利润(净亏损以"-"号填
                                         35,928,815.69          36,670,657.54          23,378,642.15          23,644,364.07
列)
     归属于母公司所有者的净
                                         36,058,046.54          36,670,657.54          23,644,364.07          23,644,364.07
利润
     少数股东损益                          -129,230.85                                   -265,721.92
六、每股收益:
     (一)基本每股收益                          0.199                                         0.235
     (二)稀释每股收益                          0.199                                         0.235
4.3年初到报告期末利润表
编制单位:华兰生物工程股份有限公司                            2007年1-9月                          单位:(人民币)元
                                                    本期                                       上年同期
             项目
                                         合并                 母公司                  合并                  母公司
一、营业总收入                          273,533,404.27         265,415,168.74         265,239,837.94        247,161,742.59
其中:营业收入                          273,270,589.16         265,152,353.63         264,449,068.94        246,370,973.59
       利息收入
       已赚保费
       手续费及佣金收入
二、营业总成本                          176,601,814.92         160,948,890.32         187,707,943.96        168,637,033.72
其中:营业成本                          129,827,042.57         127,511,018.48         153,100,543.32        136,762,328.47
       利息支出
       手续费及佣金支出
       退保金
       赔付支出净额
       提取保险合同准备金净

       保单红利支出
       分保费用
       营业税金及附加                       306,188.31                                     30,646.46
       销售费用                          16,947,893.26          16,897,356.18          19,338,126.98         19,233,395.98
       管理费用                          26,398,646.75          15,953,420.14          14,009,170.56         12,314,756.11
       财务费用                           1,389,481.53             417,985.57             252,382.62           -626,506.26
       资产减值损失                       1,545,665.02             -17,787.53             277,780.96            253,766.36
  加:公允价值变动收益(损失
以"-"号填列)
       投资收益(损失以"-"号
                                                                                                               -796,694.77
填列)
         其中:对联营企业和合
营企业的投资收益
     汇兑收益(损失以"-"号填
列)
三、营业利润(亏损以"-"号填
                                         96,931,589.35         104,466,278.42          77,531,893.98         77,728,014.10
列)
  加:营业外收入                              3,159.12               1,000.00             819,902.61            819,902.61
  减:营业外支出                            779,689.10             692,506.74           4,569,899.79          4,569,899.79
     其中:非流动资产处置损失                                                           4,274,264.92          4,274,264.92
四、利润总额(亏损总额以"-"
                                         96,155,059.37         103,774,771.68          73,781,896.80         73,978,016.92
号填列)
  减:所得税费用                          9,997,675.04           9,422,469.11           9,911,954.05          9,805,390.08
五、净利润(净亏损以"-"号填
                                         86,157,384.33          94,352,302.57          63,869,942.75         64,172,626.84
列)
     归属于母公司所有者的净
                                         87,639,028.62          94,352,302.57          64,172,626.84         64,172,626.84
利润
     少数股东损益                        -1,481,644.29                                   -280,056.37
六、每股收益:
     (一)基本每股收益                          0.484                                         0.639
     (二)稀释每股收益                          0.484                                        0.639
4.4年初到报告期末现金流量表
编制单位:华兰生物工程股份有限公司                            2007年1-9月                          单位:(人民币)元
                                                    本期                                       上年同期
             项目
                                         合并                 母公司                  合并                  母公司
一、经营活动产生的现金流量:
     销售商品、提供劳务收到的
                                        317,177,560.29         308,920,040.78         307,614,517.89        285,306,485.05
现金
     客户存款和同业存放款项
净增加额
     向中央银行借款净增加额
     向其他金融机构拆入资金
净增加额
     收到原保险合同保费取得
的现金
     收到再保险业务现金净额
     保户储金及投资款净增加

     处置交易性金融资产净增
加额
     收取利息、手续费及佣金的
现金
     拆入资金净增加额
     回购业务资金净增加额
     收到的税费返还                                                                     1,712,218.46            526,494.89
     收到其他与经营活动有关
                                         26,925,401.86           7,174,418.26           2,737,238.83          2,462,649.96
的现金
       经营活动现金流入小计             344,102,962.15         316,094,459.04         312,063,975.18        288,295,629.90
     购买商品、接受劳务支付的
                                        115,512,814.26         112,101,495.37         194,720,796.31        183,917,925.25
现金
     客户贷款及垫款净增加额
     存放中央银行和同业款项
净增加额
     支付原保险合同赔付款项
的现金
     支付利息、手续费及佣金的
现金
     支付保单红利的现金
     支付给职工以及为职工支
                                         35,181,997.22          28,348,170.82          11,340,735.22          10,336,454.19
付的现金
     支付的各项税费                      37,359,545.87          31,324,738.51          46,017,406.06          43,783,755.97
     支付其他与经营活动有关
                                         78,122,423.15          44,562,278.90          35,514,550.76          30,592,472.26
的现金
       经营活动现金流出小计             266,176,780.50         216,336,683.60         287,593,488.35         268,630,607.67
         经营活动产生的现金
                                         77,926,181.65          99,757,775.44          24,470,486.83          19,665,022.23
流量净额
二、投资活动产生的现金流量:
     收回投资收到的现金
     取得投资收益收到的现金
     处置固定资产、无形资产和
其他长期资产收回的现金净额
     处置子公司及其他营业单
                                                                                          110,000.00             110,000.00
位收到的现金净额
     收到其他与投资活动有关
的现金
       投资活动现金流入小计                                                               110,000.00             110,000.00
     购建固定资产、无形资产和
                                        110,916,430.47          36,766,321.73          66,857,733.14          62,298,320.83
其他长期资产支付的现金
     投资支付的现金                                             64,626,500.00          24,225,000.00          24,225,000.00
     质押贷款净增加额
     取得子公司及其他营业单
位支付的现金净额
     支付其他与投资活动有关
                                         43,600,000.00          93,600,000.00          10,344,770.00
的现金
       投资活动现金流出小计             154,516,430.47         194,992,821.73         101,427,503.14          86,523,320.83
         投资活动产生的现金
                                       -154,516,430.47        -194,992,821.73        -101,317,503.14         -86,413,320.83
流量净额
  三、筹资活动产生的现金流
量:
     吸收投资收到的现金
     其中:子公司吸收少数股东
投资收到的现金
     取得借款收到的现金                 165,000,000.00          95,000,000.00         115,000,000.00          85,000,000.00
     发行债券收到的现金
     收到其他与筹资活动有关
的现金
       筹资活动现金流入小计             165,000,000.00          95,000,000.00         115,000,000.00          85,000,000.00
     偿还债务支付的现金                  95,000,000.00          65,000,000.00          24,000,000.00
     分配股利、利润或偿付利息
                                          5,713,825.32           2,452,513.13          29,557,922.25         28,407,624.25
支付的现金
     其中:子公司支付给少数股
东的股利、利润
     支付其他与筹资活动有关
的现金
       筹资活动现金流出小计             100,713,825.32          67,452,513.13          53,557,922.25          28,407,624.25
         筹资活动产生的现金
                                         64,286,174.68          27,547,486.87          61,442,077.75          56,592,375.75
流量净额
四、汇率变动对现金及现金等价
                                            -90,817.77             -90,817.77              -3,166.72              -3,166.72
物的影响
五、现金及现金等价物净增加额            -12,394,891.91         -67,778,377.19         -15,408,105.28         -10,159,089.57
     加:期初现金及现金等价物
                                        197,698,859.34         154,961,131.08         199,053,202.77         152,651,188.91
余额
六、期末现金及现金等价物余额            185,303,967.43          87,182,753.89         183,645,097.49         142,492,099.34

    4.5审计报告
    审计意见:未经审计



    华兰生物工程股份有限公司
    董事长:安康
    2007年10月25日
数据加载中...
prevnext
手机查看股票